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Background: Delivery of a high concentration of anticancer drugs specifically to cancer cells 
remains the biggest challenge for the treatment of multidrug-resistant cancer.   Poloxamers 
and D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) are known inhibitors of 
P-  glycoprotein (P-gp). Mixed micelles prepared from Poloxamer 407 and TPGS may increase the 
therapeutic efficacy of the drug by delivering high concentrations inside the cells and inhibiting 
P-gp. Gambogic acid (GA) is a naturally derived novel anticancer agent, but poor solubility and 
toxic side effects limit its use. In this study, we have developed Poloxamer 407 and TPGS mixed 
micelle-encapsulating GA for the treatment of breast and multidrug-resistant cancer.
Methods: GA-loaded Poloxamer 407/TPGS mixed micelles were prepared using a thin film 
hydration method, and their physicochemical properties were characterized. Cellular accumula-
tion and cytotoxicity of the GA-loaded Poloxamer 407/TPGS mixed micelles were studied in 
breast cancer cells, MCF-7 cells, and multidrug-resistant NCI/ADR-RES cells.
Results: The diameter of GA-loaded Poloxamer 407/TPGS mixed micelles was about 
17.4 ± 0.5 nm and the zeta potential -13.57 mV . The entrapment efficiency of GA was 
93.1% ± 0.5% and drug loading was about 9.38% ± 0.29%. Differential scanning calorimetry 
and X-ray powder diffraction studies confirmed that GA is encapsulated by the polymers. The 
in vitro release studies showed that mixed micelles sustained the release of GA for more than 
4 days. Results from cellular uptake studies indicated that GA-loaded Poloxamer 407/TPGS 
mixed micelles had increased cellular uptake of GA in NCI/ADR-RES cells.   Cytotoxicity 
of GA-loaded Poloxamer 407/TPGS mixed micelles was found to be 2.9 times higher in 
multidrug-resistant NCI/ADR-RES cells, and 1.6 times higher in MCF-7 cells, as compared 
with unencapsulated GA.
Conclusion: This study suggests that Poloxamer 407/TPGS mixed micelles can be used as a 
delivery system for GA to treat breast and multidrug-resistant cancer.
Keywords: gambogic acid, Poloxamer 407, TPGS, P-glycoprotein, multidrug resistance, breast 
cancer
Introduction
Multidrug resistance (MDR) is the phenomenon of simultaneous resistance to many 
structurally unrelated cytotoxic agents, and is one of the most formidable challenges 
in the field of cancer therapy. A common mechanism of MDR is the active export 
of drugs from cancer cells by the overexpression of P-glycoprotein (P-gp) and other 
adenosine triphosphate (ATP)-binding cassette transporters.1,2 The use of Poloxamer 
block copolymers as a drug delivery vehicle to treat MDR cancers is a rapidly devel-
oping area for cancer chemotherapy. Poloxamers have been shown to reverse MDR 
by inhibiting the P-gp pump.3,4
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Gambogic acid (GA) is the principal active ingredient 
of gamboge, the resin found in trees of the genus 
Garcinia. GA possesses diverse biological properties such 
as anti-inﬂammatory, antioxidant, antiviral, anti-infectious, 
and neuroprotective effects.5,6 Additionally, GA inhibits 
the growth of different types of cancer including gastric 
cancer, lung carcinoma, prostate cancer, melanoma, hepato-
carcinoma, and breast cancer.7–11
Several possible mechanisms are proposed for the 
anticancer effect of GA, such as induction of apoptosis, 
microtubule depolymerization, and downregulation of 
telomerase activity.7,12,13 Gu et al7 showed that GA can 
induce apoptosis in MCF-7 cancer cells through upregulation 
of p53 and downregulation of Bcl-2 proteins. GA also 
depolymerized microtubules and elevated the phosphorylation 
levels of JNK1 and p38, which caused G2/M cell cycle arrest 
and apoptosis in MCF-7 cells.12 GA significantly inhibited 
the adhesion, migration, and invasion of the cancer cells 
in vitro.12,14 Wang et al15 describe the potential role of GA 
to reverse docetaxel resistance though downregulation of 
survivin in gastric cancer cells. Survivin might play a key 
role in MDR in the presence of P-gp, and this might repre-
sent a novel strategy for modulating MDR in cancer cells.2 
Recently, a selective apoptotic induction of GA on cancer 
cells compared with normal cells suggests GA might be 
an effective anticancer drug candidate with low toxicity to 
normal cells.16
The poor water solubility of GA has limited its use. 
Several approaches have been used to improve the solubil-
ity of the GA, such as conjugation with L-arginine or use of 
polyoxylated castor oil (Cremophor EL®; BASF SE, Ludwig-
shafen, Germany),17 but lethal allergic reaction and ulceration 
was observed with L-arginine containing formulations. The 
Cremophor EL-containing formulation had several side 
effects such as cardiotoxicity, nephrotoxicity, neurotoxicity, 
and hypersensitivity reactions.18
Polymeric micelle systems were recognized as one of 
the most promising strategies to deliver poorly soluble anti-
cancer drugs.19–22 Polymeric micelles made of amphiphilic 
copolymers consist of a core shell structure formed by 
self-assembly of a hydrophobic block as an internal core 
and a hydrophilic block as a surrounding shell. Poorly 
soluble drugs can be made soluble within the hydrophobic 
inner core of a micelle and hydrophilic shell interface the 
biological media.23 As a result, micelles can substantially 
improve solubility and bioavailability of various hydro-
phobic drugs. The nanometer size (,100 nm) of micelles 
allows higher accumulation and delivery of encapsulated 
anticancer drugs, via the enhanced permeability and 
retention effect.24
Among a number of natural and synthetic polymers used 
to form polymeric micelles, Poloxamer 407, a US Food and 
Drug Administration-approved polymer, is the most attrac-
tive due to its biocompatibility, biodegradability, and low 
toxicity. Poloxamer block copolymer consists of ethylene 
oxide (EO) and propylene oxide (PO) blocks that are arranged 
in a basic EOx–POy–EOx structure. The PO core can serve as a 
“pool” and the hydrophobic drug can be incorporated into the 
hydrophobic PO core, while the hydrophilic corona maintains 
the dispersion stability of Poloxamer micelles. Incorporation 
of drugs into micelles leads to increased solubility, metabolic 
stability, and circulation time of the drug.25,26
D-α-Tocopheryl polyethylene glycol 1000 succinate 
(TPGS), a derivative of natural vitamin E (α-tocopherol) and 
polyethylene glycol 1000, has been widely applied in the food 
and drug industry as solubilizer, absorption enhancer, and 
a vehicle for lipid-based drug delivery formulations. It has 
also been found that TPGS enhances the solubility, inhibits 
P-gp-mediated multidrug resistance, and increases the oral 
bioavailability of anticancer drugs.27 It was also reported that 
succinate esters of vitamin E behave as potent proapoptotic 
agents selective for cancer cells.28 Mixed micelles manifest 
synergistic properties, such as increased micelle stability and 
drug-loading efficiency, superior to those of the individual 
components.29
We hypothesize that GA-loaded mixed micelles made of 
Poloxamer 407 and TPGS may allow a better nanoformula-
tion, more stability, and higher anticancer efficiency in resis-
tant breast cancer. GA-loaded mixed Poloxamer 407/TPGS 
micelles were prepared and their physical properties were 
characterized. The in vitro cellular uptake and cytotoxicity 
against breast cancer cells, MCF-7, and multidrug resistant 
NCI/RES-ADR cells were studied.
Methods and materials
Poloxamer 407 was obtained as a gift from BASF (T  arrytown, 
NY), TPGS was purchased from Sigma-Aldrich (St Louis, 
MO). GA was purchased from 2A PharmaChem (Lisle, IL). 
All other reagents and buffer solutions were of analytical 
grade. Distilled and deionized (DI) water was used in all 
experiments.
Preparation of micelles
GA-loaded Poloxamer 407/TPGS mixed micelles were pre-
pared by thin film hydration method as described earlier in 
Zhang et al.26 Brieﬂy, GA (9 mg), Poloxamer 407 (68 mg), 
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and TPGS (23 mg) were dissolved in 3 mL acetonitrile 
in a round bottom ﬂask. The solvent was evaporated by 
rotary evaporation at 40°C for 1 hour to obtain a solid 
GA/copolymer matrix. Residual acetonitrile remaining 
in the film was removed under vacuum overnight at room 
  temperature. The resultant thin film was hydrated with 4 mL 
water at 40°C for 30 minutes to obtain a micelle solution, 
which was then filtrated through 0.2 µm filter membrane 
to remove the unincorporated GA aggregates, followed 
by lyophilization. Empty Poloxamer 407/TPGS mixed 
micelles were also prepared as described above, excepting 
the addition of GA.
Critical micelle concentration (CMC) 
determination
To determine the CMC of binary mixture of Poloxamer 407/
TPGS in DI water, an ultraviolet-visible (UV-Vis) spectros-
copy method was used, using iodine as a hydrophobic probe.30 
The KI/I2 standard solution was prepared by dissolving 0.5 g 
of iodine and 1 g of potassium iodide in 50 mL DI water. 
Samples of polymer solution with concentrations ranging 
from 0.00001% to 0.1% were prepared. To each of the Polox-
amer 407/TPGS binary mixture (molar ratio 3:7) solutions, 
25 µL KI/I2 standard solution was added. The mixtures were 
incubated for 12 hours in a dark room at room temperature 
before measurement. The ultraviolet absorbance value of 
varying polymer concentrations at 366 nm was measured 
using a UV-Vis spectrometer (DU 800; Beckman Coulter, 
Indianapolis, IN). Experiments were performed in triplicate. 
The absorption intensity was plotted against the logarithm of 
polymer concentration. The CMC values correspond to the 
concentration of the polymer at which the sharp increase in 
absorbance is observed.
Particle size and zeta potential analysis
Particle mean size and size distribution were measured by 
the dynamic light scattering method using a Brookhaven 
Particle Size/Zeta Potential analyzer (ZetaPALS, Brookhaven 
Instruments, Holtsville, NY). The analyses were performed with 
5 mW He-Ne laser (632.8 nm) at a scattering angle of 90° at 
25°C. Each freeze dried or freshly prepared sample was diluted 
to the appropriate concentration using DI water. The reported 
experimental result of each sample was expressed as a mean 
size ± standard deviation (SD) for three separate experiments.
Drug loading and encapsulation efficiency
Drug loading (DL%) and encapsulation efficiency (EE%) 
were determined by UV-Vis-spectrophotometry at maximum 
absorbance of 361 nm. The micellar solution was suitably 
diluted with acetonitrile prior to determination. DL% and 
EE% were calculated using following equations:26
  DL% =   Weight of the drug in micelles 
/Weight of the feeding polymer and drug  
× 100    (1)
  EE% =   Weight of the drug in micelles 
/Weight of the feeding drug × 100  (2)
Differential scanning calorimetry (DSC)
The physical state of GA encapsulated in the mixed micelles 
and the free GA were examined by DSC using DSC Q200 
(TA Instruments, New Castle, DE) under liquid nitrogen at 
a ﬂow rate of 50 mL per minute. Then, 5 mg of the sample 
was heated from 0°C to 300°C at a temperature-rising speed 
of 10°C per minute.
X-ray powder diffraction analysis (XRPD)
XRPD experiments were performed from 2° to 40° (2θ angle) 
using a D8 X-Ray diffractometer system (Bruker AXS, 
Madison, WI) with a copper anode source (Kα, λ = 1.5406 Å) 
with a filtered flat lithium fluoride secondary beam 
monochromator. The divergence, receiver, and detector slit 
widths were 2 mm; the scatter slit width was 0.6 mm.
In vitro drug release
To create a pseudo-sink condition, the in vitro release 
behaviors of GA from mixed micelles were monitored 
in phosphate-buffered saline (PBS) (pH 7.4) with 0.5% 
Tween® 80 (ICI Americas Inc, Wilmington, DE).26 Brieﬂy, 
10 mg of GA-loaded mixed micelles was introduced into 
a dialysis membrane bag (MWCO 6000–8000 Da), and 
the sealed dialysis bag was incubated in 20 mL of release 
media into an orbital shaker (VWR International, LLC, 
Suwanee, GA) at 37°C and 100 rpm. At predetermined time 
intervals, a sample was withdrawn and complete release 
media was replaced with fresh release media. The concentra-
tion of GA in a sample was measured by the DU 800 UV-Vis 
spectrophotometer at maximum absorbance of 360 nm and 
the cumulative release percentage was calculated. For com-
parison, the release of GA from dimethyl sulfoxide solution 
was conducted under the same conditions.31
Cell culture
Breast cancer MCF-7 cells were obtained from the American 
Type Culture Collection (ATCC; Manassas, VA) and 
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multidrug-resistant NCI/ADR-RES cells were obtained 
from the National Cancer Institute (Bethesda, MD). Cells 
were cultured in RPMI 1640 media supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin (all from 
Mediatech, Manassas, VA).
Cellular internalization study
MCF-7 and NCI/ADR-RES cells grown on two-well LabTek 
chambered glass slides (Nalge Nunc International, Roch-
ester, NY) at a density of 5 × 104 cells/well and incubated 
for 24 hours. One milliliter of media containing free GA 
or GA-loaded mixed micelles equivalent to 1 µM of GA 
was added to the cells. After incubation for 4 hours, cells 
were washed three times with ice cold PBS, fixed with 4% 
paraformaldehyde. A cover slip was mounted on the slide 
and the slide was photographed using a Nikon Eclipse Ti 
(Nikon Instruments Inc, Melvill, NY) confocal laser scanning 
microscope (CLSM).
In vitro cytotoxicity study
In vitro cytotoxicity of GA-loaded mixed micelles was 
determined using 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Brieﬂy, MCF-7 
and NCI/ADR-RES cells were transferred to 96-well tis-
sue culture plates at a density of 2 × 103 cells per well and 
5 × 103 cells per well, respectively, 24 hours prior to treat-
ment. The medium was then replaced with fresh medium 
containing free GA, GA-loaded micelles, and blank micelles 
at different concentrations. The culture medium without any 
drug formulation was used as the control. After 72 hours of 
incubation at 37°C and 5% CO2, media was removed and 
cells were washed twice with sterile PBS. Then 50 µL of 
MTT solution (0.5 µg per mL) was added to each well and 
further incubated for 4 hours at 37°C. Medium was removed 
and 100 µL dimethyl sulfoxide was added to each well to 
dissolve the purple formazan crystal converted from MTT. 
Cell viability was assessed by absorbance at 570 nm measured 
on a NOVOstar micro plate reader (BMG Labtech Inc, Cary, 
NC) and the concentration at which 50% of growth is inhibited 
(IC50) was calculated by GraphPad Prism 5.0 (GraphPad 
Software, La Jolla, CA).
Statistical analysis
Data are represented as means ± SD from at least three sepa-
rate experiments. Statistical significance was assessed using 
Student’s t-test. Differences were considered significant at 
P , 0.05.
Results and discussion
CMC determination
The CMC of the micelles inﬂuences their in vitro and in 
vivo stability. Low CMC values of Poloxamer 407/TPGS 
binary mixture underlie high stability of Poloxamer 407/
TPGS mixed micelles in solutions upon dilution. In this 
study, the formation of micelles was monitored by using 
iodine (I) as a hydrophobic probe. Solubilized I2 prefers 
to participate in the hydrophobic microenvironment of 
Poloxamer copolymer, causing the conversion of I3
- to I2 
from the excess potassium iodide (KI) in the solution. The 
absorbance intensity of I2 has been plotted as a function of 
polymer concentration in Figure 1 and the CMC of Polox-
amer 407/TPGS binary mixture was found to be 0.0013% 
w/v. The low CMC of the micelles suggests high stability 
and ability to maintain integrity even upon dilution in the 
blood circulation.
Particle size distribution
To achieve longevity during systemic circulation, the 
micelles must be small enough to evade detection and 
destruction by the reticulo-endothelial system (RES). The 
average micelle size and the unimodal size distribution of 
both empty and GA-loaded Poloxamer 407/TPGS mixed 
micelles are illustrated in Figure 2A and B, indicating the 
formation of nanosized mixed micelles. The mean diam-
eter of blank micelles as well as GA-loaded Poloxamer 
407/TPGS mixed micelles was close to 16.6 ± 0.1 nm and 
17.4 ± 0.5 nm respectively, with an acceptable polydispersity 
index between 0.1–0.2. Encapsulating the GA in the micelles 
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Figure 1 Plot of ultraviolet absorbance of I2 versus concentration of Poloxamer 
407/TPGS mixed micelles (molar ratio 3:7) in water. Critical micelle concentration 
value was calculated by corresponding polymer concentration at which a sharp 
increase in absorbance is observed.
Abbreviation: TPGS, D-α-Tocopheryl polyethylene glycol 1000 succinate.
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did not increase the micelle average size and size distribu-
tion. It was found that there was no increase in the particle 
size of empty and GA-loaded Poloxamer 407/TPGS mixed 
micelles after freeze drying (Figure 2C and D). After 
6 months in storage at 4°C, the drug content of freeze dried 
GA-loaded Poloxamer 407/TPGS mixed micelles did not 
change, indicating that lyophilization is a good choice for 
storage of mixed micelles.
Zeta potential
Both empty and GA-loaded Poloxamer 407/TPGS mixed 
micelles were negatively charged with zeta potential 
of about -8.52 mV and -13.57 mV, respectively. In the 
structure of Poloxamer 407 both the polypropylene oxide and 
polyethylene oxide segments were nonionic, so the change of 
the surface charge of the micelles should result from addition 
of GA and/or TPGS. The free carboxylic group of GA can dis-
sociate and result in the anionic property for GA. Therefore, 
the absolute value of zeta potential was increased by addition 
of drug. The increased negative surface charge of GA might 
be attributed to TPGS, which enhanced the solubility of GA 
and more anionic GA was present in solution.
Drug loading and encapsulation efficiency
DL% of the GA-loaded Poloxamer 407/TPGS mixed micelles 
was about 9.38% ± 0.29% and the EE% was 93.1% ± 0.5%. 
The encapsulation of GA in the mixed micelle system is high 
at this drug loading.
DSC and XRPD analysis
The physical status of GA inside the micelles was examined 
by DSC and XRPD. DSC thermogram (Figure 3A) revealed 
endothermic peaks of GA and Poloxamer 407/TPGS. 
Thermogram for physical mixture shows all the endothermic 
peaks of GA and Poloxamer/TPGS while the thermogram 
for blank Poloxamer 407/TPGS mixed micelles only shows 
endothermic peaks of polymers. The thermogram of GA-
loaded Poloxamer 407/TPGS micelles shows all endothermic 
peaks of polymers as shown in the blank micelles thermo-
gram, but the characteristic peaks (at 140°C) of GA was 
absent, which confirmed the encapsulation of GA inside the 
Poloxamer 407/TPGS micelles.
XRPD diffraction spectra (Figure 3B) shows ch  aracteristic 
diffraction peaks of GA, which were visible in the pattern 
obtained for GA as well as for the physical mixture of GA, 
Poloxamer 407, and TPGS, but disappeared in the pattern 
of GA-loaded Poloxamer 407/TPGS, especially around 
4°C–10°C. This indicates that GA was encapsulated in the 
polymeric micelles in molecular or amorphous state and there 
was no free drug on the surface of micelles.
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Figure 2 Particle size distribution of blank micelles (A and C) and gambogic acid-loaded 
Poloxamer 407/TPGS mixed micelles (B and D), before freeze drying (A and B) and after 
freeze drying (C and D). The x-axis is in logarithmic scale from 0.5 to 500 (the middle 
two points on the x-axis shown by the dashed line are 5 and 50 nm, respectively.
Abbreviation: TPGS, D-α-Tocopheryl polyethylene glycol 1000 succinate.
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Figure 3 (A) Differential scanning calorimetric thermogram and (B) X-ray powder 
diffraction spectra of gambogic acid (GA) (green lines), physical mixture of GA, 
Poloxamer  407  and  TPGS  (red  lines),  blank  poloxamer/TPGS  mixed  micelles 
(Black lines) and GA-loaded poloxamer/TPGS mixed micelles (blue lines).
Abbreviations: GA, gambogic acid; TPGS, D-α-Tocopheryl polyethylene glycol 
1000 succinate.
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In vitro drug release
The in vitro release of GA from mixed micellar formula-
tion under sink conditions was investigated by dialysis 
method with 0.5% Tween 80 solution as release medium. 
As shown in Figure 4, about 30% of GA was released from 
mixed micelles within the first 4 hours, while almost 100% 
of GA was released from the GA solution during the same 
time period. After 4 days approximately 90% of the GA 
was released from GA-loaded Poloxamer 407/TPGS mixed 
micelles. The micellar carrier can not only solubilized the 
poorly soluble GA, but also sustained the GA release for 
more than 4 days. Drug diffusion, polymer erosion or swell-
ing might be possible mechanisms for release of GA from 
micelles.32
Cellular uptake study
To evaluate the cellular internalization of GA-loaded 
Poloxamer 407/TPGS mixed micelles, the cellular uptake 
by MCF-7 and NCI/ADR-RES cells were investigated. 
  Figure 5A1–3 and B1–3 shows the CLSM images of free GA 
and GA-loaded Poloxamer 407/TPGS mixed micelles 
respectively, in MCF-7 cells. GA itself was ﬂuorescent under 
the CLSM and the images show that, similar to free GA, 
GA-loaded Poloxamer 407/TPGS mixed micelles also 
distributed throughout the cytoplasm. This indicates that 
the mixed micelles have been taken up by the cells and are 
located inside the cells. There is equal or higher uptake of 
GA-loaded Poloxamer 407/TPGS mixed micelles in MCF-7. 
The uptake of free GA may be due to the binding affinity 
of GA for transferrin receptors33 while the micelles are 
internalized by endocytosis. Figure 5C1–3 and D1–3 show 
the CLSM images of free GA and GA-loaded Poloxamer 
407/TPGS mixed micelles respectively, in NCI/ADR-RES 
cells. It was clear that the intensity of the green ﬂuores-
cence inside the cells treated with GA-loaded Poloxamer 
407/TPGS mixed micelles (Figure 5D) was much greater 
than that of the free GA (Figure 5C). This indicates an 
enhanced uptake of GA-loaded Poloxamer 407/TPGS mixed 
micelles in NCI/ADR-RES cells as compared to free GA. 
NCI/ADR-RES cells expressing the P-gp may have higher 
efﬂux of GA from the cells, but mixed micelles taken up 
by cells via endocytosis are not subject to efﬂux by P-gp. 
Also, Poloxamer 407/TPGS mixed micelles may inhibit the 
P-gp efﬂux pump.34,35
In vitro cytotoxicity study
Figure 6A shows the in vitro cytotoxic effect of free GA and 
GA-loaded Poloxamer 407/TPGS mixed micelles in MCF-7, 
and Figure 6B shows it in NCI/ADR-RES cells. The results 
indicate that GA formulated in the polymeric micelles has 
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Figure 4 In vitro release profile of gambogic acid (GA)-loaded Poloxamer 407/TPGS 
mixed micelles and GA solution in DMSO. Drug release study was performed at 37°C 
under shaking (100 rpm) which was monitored using a dialysis bag containing phosphate-
buffered saline with addition of 0.5% Tween-80 as a sink solution at pH 7.4. 
Notes: Mean ± SD, n = 3.
Abbreviations:  DMSO,  dimethyl  sulfoxide;  GA,  gambogic  acid;  TPGS,  D-α-
Tocopheryl polyethylene glycol 1000 succinate; SD, standard deviation.
Figure 5 Cellular internalization of gambogic acid (GA) (A and C) and GA-loaded 
poloxamer/TPGS mixed micelles (B and D) by confocal laser scanning microscopy 
in breast cancer MCF-7 cells (A and B) and multidrug resistant NCI/ADR-RES 
cells (C and D) after 4 hours of incubation. Images show an increased uptake of 
GA-loaded micelles inside the multidrug resistant NCI/ADR-RES cells.
Abbreviations: TPGS, D-α-Tocopheryl polyethylene glycol 1000 succinate.
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shown advantages in achieving higher cytotoxicity than the 
free GA (Figure 7). The IC50 of GA-loaded Poloxamer 407/
TPGS mixed micelles (0.44 ± 0.02 µM) in MCF-7 cells which 
is about 1.6 fold less than the free GA (0.71 ± 0.06 µM) 
(P , 0.05) and the IC50 of GA-loaded Poloxamer 407/TPGS 
mixed micelles (0.86 ± 0.01 µM) in NCI/ADR-RES cells was 
found to be 2.9 fold less than the free GA (2.5 ± 0.08 µM) 
(P , 0.01). The lower cytotoxicity of unencapsulated GA 
may be due to its efﬂux by P-gp pumps. On the other hand, 
GA-loaded Poloxamer 407/TPGS mixed micelles are taken 
up by cells via endocytosis, and are not subject to efﬂux by 
P-gp. This allows sustaining the drug concentration inside 
the cells which results in a higher cytotoxic effect, which 
is also reported in the literature.30,36,37 Another explanation 
for improved cytotoxicity of GA-loaded mixed micelles 
was the effect of Poloxamer 407 and TPGS, which are well 
known P-gp inhibitors and also reduce drug efﬂux.34,35 Empty 
Poloxamer 407/TPGS mixed micelles had no significant 
effects on the viability of MCF-7 and NCI/ADR-RES cells 
at concentrations up to 17.4 µg/mL (Figure 6C), which is 
much higher than the concentration needed for IC50 of GA-
loaded mixed micelles. The anticancer activity of TPGS 
is reported to be related to its unique apoptosis-inducing 
properties via the generation of reactive oxygen species. This 
might be the reason for toxicity of empty mixed micelles to 
cancer cells at a higher concentration.38,39 The P-gp inhibi-
tion by the Poloxamer 407/TPGS mixed micelles makes 
these micelles a better nanocarrier than other micelles such 
as PEG-PCL40 and chitosan micelles41 to treat multi-drug 
resistant cancer.
Conclusion
The purpose of this study was to design mixed micelles 
composed of Poloxamer 407 and TPGS loaded with the 
poorly soluble natural anticancer agent, GA. The micelles 
have a low CMC, small particle size and high encapsula-
tion efficiency. GA release was sustained as a result of 
encapsulation into the inner core of the micelles. GA 
encapsulation by Poloxamer 407/TPGS mixed micelles 
also demonstrated an equal or increased cellular uptake 
and increased in vitro cytotoxicity compared to free GA in 
breast cancer cells MCF-7 as well as in multidrug resistant 
NCI/ADR-RES cells. Results su  ggested that GA encapsu-
lated Poloxamer 407/TPGS mixed micelles will be a good 
nanoformulation to treat breast and multidrug-resistant 
cancer. Future studies will be focus on in vivo evaluation 
of GA-loaded Poloxamer 407/TPGS mixed micelles.
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Figure 6 In vitro cytotoxicity of free gambogic acid (GA), GA-loaded Poloxamer 407/TPGS mixed micelles, blank poloxamer/TPGS mixed micelles in (A) breast cancer 
MCF-7 cells and (B) multidrug resistant NCI/ADR-RES cells after 72 hours of incubation. (C) Cytotoxicity of different concentrations of blank poloxamer/TPGS mixed 
micelles in breast cancer MCF-7 cells and multidrug-resistant NCI/ADR-RES cells after 72 hours of incubation. 
Notes: Mean ± SD, n = 3.
Abbreviations: TPGS, D-α-Tocopheryl polyethylene glycol 1000 succinate; SD, standard deviation.
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Figure 7 IC50 values of free gambogic acid (GA) and GA-loaded Poloxamer 407/
TPGS mixed micelles in breast cancer MCF-7 cells and multidrug resistant NCI/
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Abbreviations: TPGS, D-α-Tocopheryl polyethylene glycol 1000 succinate; SD, 
standard deviation.
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